Gossamer Bio faces securities lawsuit with June 1 lead plaintiff deadline

A class action lawsuit has been filed against Gossamer Bio, Inc. (NASDAQ: GOSS), alleging securities fraud and other violations of federal securities laws. The complaint was filed by law firm Levi & Korsinsky, LLP on behalf of investors who purchased Gossamer securities between June 16, 2025, and February 20, 2026.

"To: All persons or entities who purchased or otherwise acquired securities of Gossamer Bio, Inc. (“Gossamer” or the “Company”) (NASDAQ: GOSS) between June 16, 2025, and February 20, 2026, inclusive," the law firm stated in a press release. The firm has set a deadline of June 1, 2026, for eligible investors to seek appointment as lead plaintiff in the case.

The lawsuit, identified as Daniel Kinnamon v. Gossamer Bio, Inc., centers on allegations that the company made materially false and misleading statements during the class period. Investors who suffered losses on their Gossamer Bio investments are encouraged to contact the firm to discuss their legal rights and options for recovering losses.

The legal action introduces significant uncertainty for Gossamer Bio, potentially leading to substantial legal costs and financial penalties. The allegations could also damage investor confidence in the near term, impacting the company's stock performance.

This lawsuit creates a direct financial risk for the company and its shareholders, with the outcome potentially affecting future capital-raising efforts. Investors will be closely watching for the company's formal response to the allegations and any further developments in the case before the June 1 deadline.

This article is for informational purposes only and does not constitute investment advice.